LivaNova PLC

Company Overview

LivaNova plc is a medical device manufacturer that was formed by the merger of Sorin and Cyberonics in 2019. Cyberonics manufactured neuromodulation devices. LivaNova has two business segments: Cardiovascular and Neuromodulation. Its Neuromodulation business offers systems for the treatment of chronic or recurrent depression, difficult-to-treat depression (DTD), drug-resistant epilepsy, and obstructive sleep apnea (OSA). The company claims to have introduced the first VNS therapy system in the U.S. in 1997.

Its neurostimulation devices include the Model 1000 SenTiva VNS therapy system, which delivers responsive therapy for treating refractors and drug-resistant epilepsy. The FDA-approved and CE-marked system provides automatic stimulation in response to detecting changes in heart rate potentially indicative of a seizure. SenTiva is MRI-compatible.

The Symmetry VNS system is FDA-approved and CE-marked for treating DTD. The FDA approved Symmetry as an adjunctive treatment for DTD for patients 18 and older. The company’s Aura6000 implantable device for treating OSA is approved for investigational uses only. It stimulates multiple tongue muscles via the hypoglossal nerve, opening the airway while a patient sleeps. The device was developed by ImThera Medical, which LivaNova acquired in 2018.

The company is also conducting clinical trials for its Vitaria VNS system for treating heart failure. It has developed Autonomic Regulation Therapy (ART), a novel approach to controlling heart failure by balancing the brain. The Vitaria system leverages this therapy to correct an imbalance that causes the heart not to pump enough blood.

Financial Highlights (FY 2025)

Company's Business Segments

• Cardiopulmonary : LivaNova’s Cardiopulmonary segment is engaged in the Design, Development, Manufacture, Marketing, and Selling of Cardiopulmonary products, including HLMs, Oxygenators, Autotransfusion systems, Perfusion tubing systems, Cannulae. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies and sensing technology for data-driven decision-making during CPB procedures.
• Neuromodulation : LivaNova’s Neuromodulation segment is engaged in the Design, Development, Manufacture, Marketing, selling of devices that deliver Neuromodulation therapy for treating DRE DTD. LivaNova’s principal Neuromodulation product, the VNS Therapy System, consists of an Implantable pulse generator, Connective lead that stimulates the vagus nerve; Surgical equipment to assist with the Implant procedure, Equipment, Instruction manuals enabling a treating physician to set parameters for a Patient’s pulse generator, for Epilepsy, magnets to suspend or induce nerve stimulation manually.
• Advanced Circulatory Support : LivaNova’s ACS segment was engaged in the Design, Development, Manufacture, Marketing, Selling of temporary life support products. ACS’s products, which comprise the LifeSPARC, Hemolung systems, Standalone cannulae, Accessories, including ProtekDuo and Transseptal (TandemHeart) cannulae, Simplify temporary extracorporeal cardiopulmonary life support solutions for critically ill patients.
• Other Revenue : Other revenue primarily includes rental income not allocated to segments. For the year ended December 31, 2021, other revenue includes the net revenue of the Company’s Heart Valve business, which was divested on June 1, 2021.